title: Immunoregulating properties of peptides related to tumor rejection antigens: effect on human monocytes and natural killer cells.
abstract: The authors analyzed the effect of several 15-amino acid peptides with sequences related to tumor-rejection antigens, tyrosinase, and the MAGE family on peripheral blood mononuclear cells from healthy donors cultured for periods of 1 to 7 days. Some of these peptides promoted stimulation of monocytes, manifested by phenotypic changes, release of interleukin (IL)-1a, IL-6, and tumor necrosis factor-alpha, and induction of nitric oxide synthase on differentiated CD14++/+ CD16+ DR++ monocytes. An increase in the percentage of cytotoxic monocytes (CD14+/- CD16+) containing granule-associated DNase activity was also observed. Active peptides induced the release of IL-2 and interferon-gamma. Nonspecific natural killer and lymphokine-activated killer cell-mediated cytotoxicity was also observed against classical target cell lines (K-562 and Daudi) and allogenic melanoma cell lines AC and BB, together with an increase in granule-associated DNase in the natural killer cell-enriched population. Monocytes were needed to enhance this innate response, because peptides failed to induce the release of IL-2 on monocyte-depleted peripheral blood mononuclear cells. Data show an enhancement of the rapid innate immune response by peptides related to tumor rejection antigens and suggest that they could also determine the nature of a slow and more definitive specific immune response against tumor cells.
authors.affiliation: Department of Biochemistry, University of Navarra, Pamplona, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Pérez-Díez
authors.forename: A
authors.initials: A
authors.lastname: Martínez-Crespo
authors.forename: L A
authors.initials: LA
authors.lastname: Pérez-Mediavilla
authors.forename: E
authors.initials: E
authors.lastname: Santiago
authors.forename: N
authors.initials: N
authors.lastname: López-Moratalla
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D016207:Cytokines / Q000378:metabolism; D003594:Cytoplasmic Granules / Q000201:enzymology; D003851:Deoxyribonucleases / Q000378:metabolism; D004790:Enzyme Induction / Q000276:immunology; D006801:Humans; D016130:Immunophenotyping; D020014:K562 Cells; D015979:Killer Cells, Lymphokine-Activated / Q000201:enzymology / Q000276:immunology; D007694:Killer Cells, Natural / Q000276:immunology*; D009000:Monocytes / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism; D019001:Nitric Oxide Synthase / Q000096:biosynthesis; D010455:Peptides / Q000138:chemical synthesis / Q000276:immunology* / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D010455:Peptides; D019001:Nitric Oxide Synthase; D003851:Deoxyribonucleases